These patent-pending optical contrast agents and molecular detection technologies were developed to enhance the ability of optical coherence tomography (OCT) to non-invasively map molecules in living specimens and diagnose disease where it starts. OCT utilizes low-coherence interferometry to measure the intensity of reflected or backscattered light to form images with micrometer resolution, is readily integrated with existing optical instrumentation and has application across a wide range of biological, medical, surgical, and non-biological specialties.